Cadila net profit up by 82% in third-quarter
Indian drugmaker Cadila Healthcare (BSE: 532321) posted a net profit of 1.86 billion rupees ($29.7 million), for the fiscal third-quarter ended December 31, 2013, up 82% from the corresponding period last year. The company’s shares rose nearly 6% to 904.00 rupees on the news.
The company, which also operates as Zydus Cadila, reported total income of 18.72 billion rupees, up 17% on a consolidated basis. During the quarter, the company’s business in the USA registered growth of 61% and Emerging Markets business grew by 30%.
During the quarter, the company filed 31 additional Abbreviated New Drug Applications with the US Food and Drug Administration, taking the cumulative ANDA filings for the period April-December 2013, to 49.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze